New drug AMN1126 put through early safety testing
Knowledge-focused
Completed
This early-stage trial tested the safety and tolerability of a single dose of the experimental drug AMN1126 in 18 healthy postmenopausal women. Participants received one of three different doses (150mg, 300mg, or 600mg) and were monitored for side effects and how the drug moved t…
Phase: PHASE1 • Sponsor: Amneal Pharmaceuticals, LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC